Leerink Partnrs Reduces Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for Kura Oncology in a report issued on Thursday, November 13th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of $0.18 per share for the quarter, down from their prior estimate of $0.19. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Several other equities research analysts have also recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Friday. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, August 17th. Finally, Guggenheim assumed coverage on shares of Kura Oncology in a research report on Thursday, September 4th. They issued a “neutral” rating for the company. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $25.11.

Kura Oncology Trading Up 2.1%

Shares of KURA stock opened at $11.08 on Monday. The firm’s fifty day simple moving average is $9.58 and its 200 day simple moving average is $7.55. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $16.61. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $964.18 million, a P/E ratio of -4.47 and a beta of 0.35.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The business had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers raised its position in Kura Oncology by 0.9% during the 3rd quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock worth $1,061,000 after purchasing an additional 1,039 shares during the last quarter. E Fund Management Co. Ltd. raised its position in shares of Kura Oncology by 18.9% during the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company’s stock worth $81,000 after acquiring an additional 1,951 shares during the last quarter. Profund Advisors LLC lifted its stake in shares of Kura Oncology by 11.1% in the third quarter. Profund Advisors LLC now owns 24,835 shares of the company’s stock worth $220,000 after acquiring an additional 2,478 shares during the period. Arizona State Retirement System boosted its holdings in Kura Oncology by 15.8% in the third quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock valued at $181,000 after acquiring an additional 2,802 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Kura Oncology by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock valued at $175,000 after acquiring an additional 2,976 shares during the last quarter.

Insider Activity at Kura Oncology

In other news, insider Brian T. Powl sold 8,887 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $99,356.66. Following the completion of the sale, the insider directly owned 139,689 shares in the company, valued at approximately $1,561,723.02. This trade represents a 5.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Teresa Brophy Bair sold 8,804 shares of Kura Oncology stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $11.18, for a total value of $98,428.72. Following the completion of the transaction, the insider directly owned 188,139 shares of the company’s stock, valued at $2,103,394.02. This represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 122,675 shares of company stock valued at $1,196,657. Insiders own 6.40% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.